LONDON -- Management can make all the difference to a company's success and thus its share price.
The best companies are those run by talented and experienced leaders with strong vested interests in the success of the business, held in check by a board with sound financial and business acumen. Some of the worst investments to hold are those run by executives collecting fat rewards as the underlying business goes to pot.
In this series, I'm assessing the boardrooms of companies within the FTSE 100 (INDEX: ^FTSE) . I hope to separate the management teams that are worth following from those that are not. Today I am looking at AstraZeneca (ISE: AZN.L) (NYS: AZN) , one of the FTSE's highest-yielding stocks, which is facing the well-documented challenge of its patent cliff.
Here are the key directors:
Interim chief executive
AstraZeneca currently has just one executive on its board, and he is an interim stand-in following David Brennan's ousting in the shareholder spring that saw investors rebel against high pay for poor results.
Simon Lowth had been finance director since November 2007 and stepped up in June. He was formerly an engineering industry management consultant with McKinsey, and subsequently finance director of Scottish Power.
Cutting costs and making deals
Credited with success in driving down costs at AstraZeneca, he is tipped as a possible permanent CEO. Though some may fear he lacks the necessary business background, AZN's innovative deal alongside Bristol-Myers Squibb (NYS: BMY) to acquire biotech company Amylin has bought him a lot of credibility.
Chairman Leif Johansson's appointment in April 2012 reflected the Swedish half of AZN's roots. He was CEO of Volvo for 14 years from 1997 to 2011 and since 2011 has been chairman of Ericsson. He was also a non-exec of Bristol-Myers Squibb from 1998 to 2011. That's a strong background, but leaves his hands full.
With Simon Lowth standing in as interim CEO, his deputy Julie Brown is fulfilling the role of interim CFO below board level. A chartered accountant who has previously undertaken management and strategy roles with AZN, she looks likely to step up if Lowth is confirmed as permanent CEO.
There are nine non-execs whose collective background includes a good dose of pharmaceutical and scientific expertise. The appointment in April of Graham Chipchase, CEO of Rexam, and Genevieve Berger, chief of R&D at Unilever, has injected fresh blood.
Other non-execs include John Varley, who was CEO of Barclays from 2004 to 2011 and remains chairman of AstraZeneca's remuneration committee despite the shareholder revolt, and Baroness Shriti Vadera, Gordon Brown's favorite City adviser.
I analyze management teams from five different angles to help work out a verdict. Here's my assessment:
1. Reputation --Management CVs and track record.
2. Performance --Success at the company.
Too early to judge.
3. Board composition --Skills, experience, balance.
4. Remuneration --Fairness of pay, link to performance.
Jury still out.
5. Directors' holdings --compared to their pay.
CEO has 6 million pounds' worth.
Necessarily held back by its interim composition and the short tenure of the top two, AZN's board scores a modest 14 out of 25, in the lower half of companies that I have examined so far.
For comparison, I've collated all my FTSE 100 boardroom verdicts on this summary page.
Buffett's favorite FTSE share
Let me finish by adding that legendary investor Warren Buffett has always looked for impressive management teams when pinpointing which shares to buy. So I think it's important to tell you that the billionaire stock-picker has recently acquired a substantial stake in a prominent FTSE 100 company.
A special free report from The Motley Fool -- "The One UK Share Warren Buffett Loves" -- explains Mr. Buffett's purchase and investing logic in full.
And Mr. Buffett, don't forget, rarely invests outside his native United States, which to my mind makes this British blue chip -- and its management -- all the more attractive. So why not download the report today? It's totally free and comes with no further obligation.
Are you a sophisticated investor hoping to profit from this uncertain economy? We urge you to read "10 Steps to Making a Million in the Market" today -- your wealth could be transformed. Click here now to request your free, no-obligation copy. The Motley Fool is helping Britain invest. Better.
Further Motley Fool investment opportunities:
The article The Men Who Run AstraZeneca originally appeared on Fool.com.
Tony Reading owns shares in AstraZeneca and Unilever but no other shares mentioned in this article.The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.